Author:
Schneider Tatiana C.,Kapiteijn Ellen,van Wezel Tom,Smit Jan W. A.,van der Hoeven Jacobus J. M.,Morreau Hans
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference18 articles.
1. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet [epub ahead of print].
2. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012;167(5):643–50.
3. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18(1):263–72.
4. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20–3.
5. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144(6):779–82.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献